XERS Q2 2023 Earnings — Xeris Biopharma Holdings, Inc. Revenue & Financial Results | Market Cap Arena

XERSXeris Biopharma Holdings, Inc.

$960M

Q2 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$38M+50.2% YoY

Gross Profit

$30M80.1% margin

Operating Income

-$16M-42.0% margin

Net Income

-$20M-52.2% margin

EPS (Diluted)

$-0.14

QoQ Revenue Growth

+14.5%

Cash Flow

Operating Cash Flow

-$14M

Free Cash Flow

-$15M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$329M

Total Liabilities

$315M

Stockholders' Equity

$14M

Cash & Equivalents

$46M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$38M	$25M	+50.2%
Gross Profit	$30M	$20M	+48.6%
Operating Income	-$16M	-$19M	+15.5%
Net Income	-$20M	-$26M	+24.2%

Revenue Segments

Product

$37M72%

Keveyis

$14M28%